Core Points - DBV Technologies has filed an addendum to the 2024 Universal Registration Document with the French market authority AMF [1] - The addendum updates the Corporate Governance Report regarding exceptional compensation granted to the CEO, pending approval at the Annual Combined General Meeting on June 11, 2025 [2] Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immunologic conditions with significant unmet medical needs [4] - The company utilizes its proprietary Viaskin technology platform to address food allergies through epicutaneous immunotherapy (EPIT™), which aims to desensitize the immune system to allergens [4] - Ongoing clinical trials include Viaskin Peanut for peanut allergic toddlers and children [4] Operations and Trading - DBV Technologies is headquartered in Châtillon, France, with operations in Warren, NJ, North America [5] - The company's ordinary shares are traded on Euronext Paris and its American Depositary Shares (ADSs) on the Nasdaq Capital Market [5]

Core Points - DBV Technologies will hold its Combined General Meeting on June 11, 2025, at 02:00 p.m. CEST at its headquarters in Châtillon, France [1] - The preliminary notice with the detailed agenda and instructions for participation was published on May 07, 2025 [2] - Shareholders can access preparatory documents on the Company's website, in compliance with legal provisions [3] - Shareholders wishing to receive documents by post or electronically must request them by June 06, 2025 [4] - A live webcast of the General Meeting will be available on the Company's website, with a recorded version accessible for at least the minimum legal period [5] Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immunologic conditions [6] - The Company utilizes its proprietary Viaskin technology platform to address food allergies through epicutaneous immunotherapy (EPIT™) [6] - DBV Technologies is conducting clinical trials for Viaskin Peanut in peanut allergic toddlers and children [6] - The Company is headquartered in Châtillon, France, with operations in Warren, NJ, and its shares are traded on Euronext Paris and Nasdaq [7]

Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions with significant unmet medical needs [6] - The company is investigating the use of its proprietary technology platform, Viaskin, to address food allergies through epicutaneous immunotherapy (EPIT™) [6] - DBV Technologies is committed to transforming the care of individuals with food allergies, with ongoing clinical trials for Viaskin Peanut targeting peanut allergic toddlers and children [6] Upcoming General Meeting - The Combined General Meeting is scheduled for June 11, 2025, at 02:00 p.m. CEST at the company's headquarters in Châtillon, France [1] - A preliminary notice containing the detailed agenda and draft resolutions was published on May 07, 2025, and the official meeting notice will be published on May 21, 2025 [2] - Shareholders can access preparatory documents on the company's website, and requests for documents can be made until June 06, 2025 [3][4] Webcast Information - A live webcast of the General Meeting will be available on the company's website, with a recorded version accessible within seven business days after the meeting [5]

Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions with significant unmet medical needs [3][4] - The company is headquartered in Châtillon, France, with North American operations in Warren, NJ [4] Technology and Treatment Approach - DBV Technologies is investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by hypersensitive immune reactions [3] - The VIASKIN® patch is designed to introduce microgram amounts of biologically active compounds to the immune system through intact skin, utilizing epicutaneous immunotherapy (EPIT™) [3] - EPIT™ aims to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergens, leveraging the skin's immune tolerizing properties [3] Clinical Trials and Focus Areas - The company is currently conducting ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (ages 1 to 3) and children (ages 4 to 7) [3]

Core Viewpoint - DBV Technologies reported its financial results for the first quarter of 2025, highlighting significant cash usage in operations and ongoing clinical trials, while also announcing a financing plan to support its product development [1][5]. Financial Highlights - Cash and cash equivalents decreased to $13.0 million as of March 31, 2025, from $32.5 million at the end of 2024, reflecting a net decrease of $19.5 million, primarily due to $19.7 million used in operating activities [4][8]. - The company incurred operating losses and negative cash flows since inception, with no product revenue generated to date [6]. Cash Flow Analysis - The net cash flow used in operating activities was $19.7 million for Q1 2025, compared to $34.7 million for the same period in 2024, indicating an improvement in cash flow management [21]. - The company received gross proceeds of $125.5 million on April 7, 2025, as part of a financing plan of up to $306.9 million to support the Viaskin® Peanut Patch [5]. Operating Income and Expenses - Operating income for Q1 2025 was $0.8 million, down from $1.4 million in Q1 2024, attributed to a lower French Research Tax Credit due to more activities being conducted in North America [10][12]. - Total operating expenses decreased to $27.4 million in Q1 2025 from $30 million in Q1 2024, mainly due to reduced General & Administrative expenses [13][15]. Net Loss - The net loss for the first quarter of 2025 was $27.1 million, slightly improved from a net loss of $27.3 million in the same quarter of 2024 [16][17]. Financial Position - As of March 31, 2025, total assets were $50.6 million, down from $65.7 million at the end of 2024, with liabilities increasing to $47.7 million from $38.3 million [18]. Company Overview - DBV Technologies is focused on developing treatment options for food allergies using its proprietary Viaskin technology, which aims to provide non-invasive immunotherapy [22]. - The company is currently conducting clinical trials for its Viaskin Peanut product targeting peanut allergies in young children [22].